Mesenchymal Stem Cell‐Derived Extracellular Vesicles with High PD‐L1 Expression for Autoimmune Diseases Treatment

Fang Xu,Ziying Fei,Huaxing Dai,Jialu Xu,Qin Fan,Shufang Shen,Yue Zhang,Qingle Ma,Jiacheng Chu,Fei Peng,Fangfang Zhou,Zhuang Liu,Chao Wang
DOI: https://doi.org/10.1002/adma.202106265
IF: 29.4
2021-10-23
Advanced Materials
Abstract:Autoimmune diseases are the third most common disease influencing the quality of life of many patients. Here, we develop a PD-L1+ mesenchymal stem cell (MSC) derived extracellular vesicles (MSC-sEVs-PD-L1) using lentivirus-mediated gene transfection technology for reconfiguration of the local immune microenvironment of affected tissue in autoimmune diseases. MSC-sEVs-PD-L1 exhibits an impressive ability to regulate various activated immune cells to an immunosuppressed state in vitro. More importantly, in dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) and imiquimod-induced psoriasis mouse models, we observe a significantly high accumulation of MSC-sEVs-PD-L1 in the inflamed tissues compared to the PD-L1+ MSCs. Therapeutic efficiency in both UC and psoriasis mouse disease models is demonstrated using MSC-sEVs-PD-L1 to reshape the inflammatory ecosystem in the local immune context. We develop a technology using MSC-sEVs-PD-L1 as a natural delivery platform for autoimmune diseases treatment with high clinical potential.This article is protected by copyright. All rights reserved
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
What problem does this paper attempt to address?